Abstract Search

Introduction: Agonist receptor-GLP1 (AR-GLP1) had demonstrated its utility in obese patients with diabetes type 2. Since August 2013 we have available in Spain a new AR-GLP1 with prandial action in a single daily dose, lixisenatide. There are different clinical trials that support its efficacy and security but the dates from real clinical practice are scarce.Aim: To analyse the efficacy and security in real clinical practice for the treatment of diabetic...

0 shares

ea0032p901 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Efficacy and safety of lanreotide in combination with pegvisomant in clinical practice in patients with active acromegaly with monotherapy failure

Venegas Eva , Lucas Tomas , Marazuela Monica , Cuatrecasas Guillem , Galvez Maria Angeles , Romero Enrique , Morales Francisco , Webb Susan M , Biaggeti Betina , Diaz Juan Jose , Mato Jose Antonio , Vilchez Ricardo , Bernabeu Ignacio , Paja Miguel , Pico Antonio , Domingo Manuel Puig , Soto Alfonso , on behalf of ACROCOMB study group

Introduction: ACROCOMB is a retrospective Spanish Multicenter study, designed to evaluate the efficacy (extent of tumour control) and safety of lanreotide (LAN) treatment combined with pegvisomant (PEG) or cabergoline in acromegalic patients with monotherapy failure.Methods: patients with acromegaly treated with LAN+PEG (45% of ACROCOMB patients) at 44 Spanish Endocrinology Departments were analysed.Results: 40% of patients were ma...

0 shares

Endocrine Abstracts

Clinical experience with lixisenatide in patients with obesity and type 2 diabetes

Efficacy and safety of lanreotide in combination with pegvisomant in clinical practice in patients with active acromegaly with monotherapy failure

BiosciAbstracts